Back

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

29 August 2017 (16:45 - 17:00)
Organised by:
Congress Presentation Part of: Clinical Trial Update 2 CAD and comorbidities ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Stephen Nicholls

Monash University, Melbourne (Australia)

5 More presentations in this session

Presentation thumbnail
Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen
Professor S. Nissen (Cleveland, US)
Slides Video
Presentation thumbnail
Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk
Professor T. Pedersen (Oslo, NO)
Presentation thumbnail
Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial
Professor E. Lonn (Hamilton, CA)
Slides Video
Presentation thumbnail
One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.
Doctor V. Roolvink (Zwolle, NL)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update 2

The Event

Event poster

ESC Congress 2017

29 August 2017 16:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources